Drugs.com
JUNE 11, 2025
WEDNESDAY, June 11, 2025 -- The U.S. Food and Drug Administration has approved Widaplik (telmisartan, amlodipine, and indapamide) for the treatment of hypertension in adults.The combination pill is the first and only FDA-approved triple combination.
BioPharma Drive: Drug Pricing
JUNE 11, 2025
The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to help overcome the packaging constraints of current genetic medicines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Science Daily: Pharmacology News
JUNE 11, 2025
Sea cucumbers, long known for cleaning the ocean floor, may also harbor a powerful cancer-fighting secret. Scientists discovered a unique sugar in these marine creatures that can block Sulf-2, an enzyme that cancer cells use to spread. Unlike traditional medications, this compound doesn t cause dangerous blood clotting issues and offers a cleaner, potentially more sustainable way to develop carbohydrate-based drugs if scientists can find a way to synthesize it in the lab.
Drugs.com
JUNE 11, 2025
WEDNESDAY, June 11, 2025 — Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren’t as impressive as those promised by the drugs’ clinical trials, a new study says. People taking such GLP-1.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
BioPharma Drive: Drug Pricing
JUNE 11, 2025
The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate cancer that works differently than Novartis’ Pluvicto.
Drugs.com
JUNE 11, 2025
WEDNESDAY, June 11, 2025 — The U.S. Food and Drug Administration (FDA) says it plans to use artificial intelligence (AI) to help speed the approval of new drugs and medical devices. That's one of several priorities federal officials detailed.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Science Daily: Pharmacology News
JUNE 11, 2025
A team of scientists has identified specialized neurons in the brain that store "meal memories" detailed recollections of when and what we eat. These engrams, found in the ventral hippocampus, help regulate eating behavior by communicating with hunger-related areas of the brain. When these memory traces are impaired due to distraction, brain injury, or memory disorders individuals are more likely to overeat because they can't recall recent meals.
Collaborative Drug
JUNE 11, 2025
Compare top scientific data platforms for AI-driven drug discovery. Evaluate CDD Vault, Dotmatics, Benchling & more for chemistry and biologics workflows.
Drugs.com
JUNE 11, 2025
WEDNESDAY, June 11, 2025 — Women will flock to an HPV test they can perform at home in private, a new study indicates. Cervical cancer screening more than doubled when women were offered a mail-in self-collection test for human papillomavirus.
Science Daily: Pharmacology News
JUNE 11, 2025
By using a clever quantum approach that involves two "hands" on a clock one moving quickly and invisibly in the quantum world, the other more traditionally scientists have found a way to boost timekeeping precision dramatically. Even better, this trick doesn't require a matching increase in energy use. The discovery not only challenges long-held beliefs about how clocks and physics work, but could also lead to powerful new tools in science, technology, and beyond.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drugs.com
JUNE 11, 2025
WEDNESDAY, June 11, 2025 — Want to reduce your risk of dementia and Alzheimer’s disease? Get on your bike and ride, a new study recommends. Biking regularly for transportation appears to lower risk of dementia by 19% and.
Chemical Biology and Drug Design
JUNE 11, 2025
We examined the quinolinequinones' ( QQ1- 7 ) effects on cancer cell lines. The most potent compound was QQ1 against ACHN cells with an IC50 value of 1.5 ± 0.16 μM. For better understanding, the effects of QQ1 on apoptosis, cell cycle, and oxidative stress were investigated. QQ1 inhibited ACHN cell proliferation via cell cycle arrest. The host-guest interactions of quinolinequinones were also studied in detail using thorough in silico docking simulations with pharmacokinetic studies.
Drugs.com
JUNE 11, 2025
WEDNESDAY, June 11, 2025 — With their goofy grins and feathery gills, axolotls have become stars of the pet world and video games like Minecraft. But these small, smiling salamanders are also helping scientists explore a medical mystery: Can.
Broad Institute
JUNE 11, 2025
Broad Institute and Bayer extend their cardiovascular alliance By Leah Eisenstadt June 11, 2025 Breadcrumb Home Broad Institute and Bayer extend their cardiovascular alliance Partnership will continue with renewed focus on developing new cardiovascular therapies. By Broad Communications June 11, 2025 Related news Broad Institute and Bayer expand cardiovascular alliance Broad Institute of MIT and Harvard and Bayer Healthcare expand their partnership to develop therapies for cardiovascular disease
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Science Daily: Pharmacology News
JUNE 11, 2025
NASA s CODEX experiment aboard the International Space Station is revealing the Sun like never before. Using advanced filters and a specialized coronagraph, CODEX has captured images showing that the solar wind streams of charged particles from the Sun is not a smooth, uniform flow but rather a turbulent, gusty outpouring of hot plasma. These groundbreaking observations will allow scientists to measure the speed and temperature of the solar wind with unprecedented detail, providing critical insi
Drug Patent Watch
JUNE 11, 2025
"Patent Puzzle: How to Outmaneuver Big Pharma's Monopolies As the cost of prescription medications continues to skyrocket, patients and healthcare providers are fighting back against Big Pharma's stranglehold on the market. But with billions of dollars in research and development at stake, the pharmaceutical industry will stop at nothing to protect its intellectual property.
Drug Target Review
JUNE 11, 2025
Drug development is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates. Read on to explore how multimodal AI is reshaping the future of medicine.
New Drug Approvals
JUNE 11, 2025
Gepirone CAS 83928-76-1 BMY 13805, MJ 13805, ORG 13011, Gepirona, JW5Y7B8Z18 FDA 9/22/2023, Gepirone is indicated for the treatment of major depressive disorder (MDD) in adults Exxua Weight Average: 359.474 Monoisotopic: 359.232125194 Chemical Formula C 19 H 29 N 5 O 2 4,4-dimethyl-1-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}piperidine-2,6-dione Ingredient UNII CAS InChI Key Gepirone Hydrochloride 80C9L8EP6V 83928-66-9 DGOCVISYYYQFEP-UHFFFAOYSA-N Gepirone , sold under the brand name Exxua , is
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Nvidia Developer: Drug Discovery
JUNE 11, 2025
The emergence of models like AlphaFold2 has skyrocketed the demand for faster inference and training of molecular AI models. The need for speed comes with. The emergence of models like AlphaFold2 has skyrocketed the demand for faster inference and training of molecular AI models. The need for speed comes with unique computational challenges, including algorithmic complexity, memory efficiency, and strict accuracy requirements.
Drugs.com
JUNE 11, 2025
WEDNESDAY, June 11, 2025 — Ever get the sudden urge to pee once you’ve seen your front door, slipped your key into the lock or pushed the remote to open your garage door? That’s a phenomenon known as “latchkey.
Crown Bioscience
JUNE 11, 2025
The integration of patient tumor samples and mass spectrometry is reshaping the landscape of cancer research and precision medicine. As researchers and clinicians seek to understand the complexities of cancer at a molecular level, high-resolution analytical techniques have become essential. Mass spectrometry (MS), when applied to patient-derived tumor tissues, allows for comprehensive profiling of proteins, lipids, metabolites, and post-translational modifications—offering insights into tumor bi
Drugs.com
JUNE 11, 2025
WEDNESDAY, June 11, 2025 — Many folks with inflammatory bowel disease (IBD) are turning to TikTok for advice, but they aren’t likely to receive useful and accurate information, a new study says. Analysis of 86 top IBD videos with a.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Translation
JUNE 11, 2025
Bayer Pharma has named Rege Nephro , a clinical-stage biotech startup from Japan and NXI Therapeutics , an immunotherapy startup based in Switzerland, as the first companies selected for its new Co.Lab Connect program: an initiative designed to help life sciences startups expand globally by bridging them into the Boston-Cambridge innovation ecosystem.
The Pharma Data
JUNE 11, 2025
Bristol Myers Squibb Unveils Compelling Late-Breaking Phase 3 Data Highlighting the Efficacy of Sotyktu (Deucravacitinib) in Treating Psoriatic Arthritis Bristol Myers Squibb has announced new late-breaking clinical data from the pivotal Phase 3 POETYK PsA-1 trial, reinforcing the potential of its oral, selective TYK2 inhibitor, Sotyktu® (deucravacitinib) , as an effective treatment for adults with active psoriatic arthritis (PsA).
Fierce BioTech
JUNE 11, 2025
From Fragments To Clarity: Empowering Research with Complete Patient Data Learn how natural language processing (NLP) unlocks critical insights from unstructured EHR data—like physician notes and patient narratives—to give researchers a complete view of the patient journey. See how combining structured and unstructured data advances drug development.
The Pharma Data
JUNE 11, 2025
argenx Unveils Positive Phase 2 Results for Efgartigimod in Myositis and Sjogren’s Disease at EULAR 2025 argenx SE a global immunology company dedicated to advancing treatments for severe autoimmune diseases, presented encouraging new clinical data at the 2025 European Congress of Rheumatology (EULAR), held June 11–14 in Barcelona, Spain. The data come from Phase 2 trials evaluating its investigational therapy VYVGART® (efgartigimod) for two hard-to-treat autoimmune conditions: idiopathic inflam
Fierce BioTech
JUNE 11, 2025
The biologics revolution is in full swing, and as innovation accelerates, so does the complexity of bringing these life-changing therapies to market. | The biologics revolution is in full swing, and as innovation accelerates, so does the complexity of bringing these life-changing therapies to market. With the BIO International Convention on the horizon, the corridors will be buzzing with talk of groundbreaking science.
The Pharma Data
JUNE 11, 2025
FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications, Offering Greater Convenience for Patients with B-cell Cancers BeOne Medicines Ltd. a global oncology-focused biopharmaceutical company, has received a significant regulatory milestone from the U.S. Food and Drug Administration (FDA). The agency has officially approved a new tablet formulation of BRUKINSA® (zanubrutinib) for all five of its previously approved indications.
Fierce BioTech
JUNE 11, 2025
Utilizing AI-Powered Structured Content Authoring for Global ePI Compliance Learn how to streamline ePI compliance with AI-powered tools and meet global mandates—essential insights for regulatory and content leaders. Download this whitepaper today. sdees Wed, 06/11/2025 - 13:38 Learn how to streamline ePI compliance with AI-powered tools and meet global mandates—essential insights for regulatory and content leaders.
The Pharma Data
JUNE 11, 2025
Ionis Begins Pivotal Phase 3 REVEAL Study of ION582 in Angelman Syndrome, Dosing First Patient in Global Trial Ionis Pharmaceuticals , Inc. (Nasdaq: IONS) has announced the dosing of the first patient in the Phase 3 REVEAL clinical trial, marking a significant milestone in the development of ION582, an investigational therapy for Angelman syndrome (AS).
Perficient: Drug Development
JUNE 11, 2025
Dr. Pete Cornwell, Director of Contact Center, offers a fresh perspective on customer care and is sharing his wealth of knowledge at Customer Contact Week in Las Vegas. With over 35 years of experience spanning information systems, design, architecture, and consulting for industry leaders like Terazo and Blue Cross Blue Shield North Carolina, his expertise runs deep.
The Pharma Data
JUNE 11, 2025
Dapirolizumab Pegol Demonstrates Promise in Phase 3 SLE Trial, Showing Improvements in Fatigue and Disease Activity at EULAR 2025 UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) presented comprehensive new findings from their Phase 3 PHOENYCS GO clinical trial evaluating dapirolizumab pegol (DZP) at the 2025 Annual Congress of the European Alliance of Associations for Rheumatology (EULAR) in Barcelona, Spain.
Expert insights. Personalized for you.
276 
Let's personalize your content